Vivus (VVUS) says it's been informed of a three month PDUFA extension by the FDA of for the...

|By:, SA News Editor

Vivus (VVUS) says it's been informed of a three month PDUFA extension by the FDA of for the review of its Qnexa New Drug Application from April 17 to July 17. The FDA is extending the date to provide time for a full review of the submission. Shares -7% AH.